NasdaqGM - Delayed Quote USD

Sagimet Biosciences Inc. (SGMT)

Compare
5.41 +0.01 (+0.19%)
At close: October 18 at 4:00 PM EDT
5.40 -0.01 (-0.18%)
After hours: October 18 at 7:57 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. George W. Kemble Ph.D. Executive Chairman of the Board 484k -- 1962
Mr. David A. Happel CEO, President & Director 836.18k -- 1962
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. Chief Medical Officer 649.33k -- 1963
Mr. Urs Greber Ph.D. Co-Founder -- -- --
Dr. Lucas Pelkmans Ph.D. Co-Founder -- -- --
Mr. Thierry Chauche CFO & Principal Accounting Officer -- -- 1976
Ms. Elizabeth Rozek Esq., J.D. General Counsel & Chief Compliance Officer -- -- 1972
Dr. Marie O'Farrell Ph.D. Senior Vice President of Research & Development -- -- --

Sagimet Biosciences Inc.

155 Bovet Road
Suite 303
San Mateo, CA 94402
United States
650 561 8600 https://www.sagimet.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
8

Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Corporate Governance

Sagimet Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

August 22, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 15, 2024 at 12:00 AM UTC

S-3: Offering Registrations

August 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 2, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 13, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

June 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers